Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 13Triple Negative Breast Neoplasms 5Neoplasm Metastasis 3Urinary Bladder Neoplasms 2Urethral Neoplasms 1Ureteral Neoplasms 1Sarcoma 1Refractory Solid Tumors 1Liposarcoma 1HR+HER2- Breast Cancer 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 22Nivolumab 14enfortumab vedotin 13Gemcitabine 11Specimen Handling 9Magnetic Resonance Spectroscopy 9Cisplatin 8Carboplatin 8sacituzumab govitecan 6avelumab 6Docetaxel 6atezolizumab 5Ipilimumab 5durvalumab 4Paclitaxel 4cabozantinib 3Taxes 3Mitomycin 3CTLA-4 Antigen 3tislelizumab 2relatlimab 2erdafitinib 2disitamab vedotin 2Radiosurgery 2Platinum 2Oxaliplatin 2Immunoglobulin G 2Fluorouracil 2Disulfides 2ALT-803 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × eribulin × 90 days × Clear all
NCT04579224 2026-05-29

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
184 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡